Product Description
Azidamfenicol is an organonitrogen compound and an organooxygen compound. It derives from an alpha-amino acid. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Azidamfenicol)
Mechanisms of Action: 50S Ribosomal Subunit Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Cyprus | Germany | Greece | Pakistan | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: FARMEX
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Eye Infections, Bacterial
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2013-000923-15 |
2013-000923-15 | P4 |
Completed |
Eye Infections, Bacterial |
2013-11-19 |
2025-05-06 |
Recent News Events
Date |
Type |
Title |
|---|